This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Fasoracetam (NS-105, NFC-1) is a nootropic agent belonging to the racetam family of drugs.[1][2] Although it is one of the first known and synthesized derivatives of piracetam, its research and efficacy in humans is limited.
Fasoracetam upregulates GABA receptors and may also be beneficial for ADHD either alone or in combination with stimulant medication.
Anecdotal reports of fasoracetam supplementation for nootropic purposes range from 20-100mg/day[3][4] while clinical trials have used doses up to 800mg/day (400mg BID) for the treatment of ADHD in adolescents with glutamate hypofunction due to mGluR mutations.[5]
Fasoracetam has demonstrated antiamnesic properties in animal models.[6]
Fasoracetam is a pyrrolidinone compound of the racetam family.
Pharmacology
Fasoracetam modulates cyclic adenosine monophosphate (cAMP) activity via activation of metabotropic glutamate receptors (mGlu). It appears to have activity at all three subclasses of mGlu receptors, with group I activation exhibiting a facilitatory effect, and groups II and III an inhibitory effect on cAMP.[7]
Fasoracetam is thought to increase acetylcholine release within hippocampal cells.[8] As acetycholine is involved in the function of memory, this could potentially account for its nootropic effects.
In addition, fasoracetam upregulates GABA-B receptors in rats,[9] but does not appear to affect dopamine, serotonin or norepinephrine.[10][11]
Subjective effects
In comparison to the effects of other racetam nootropics such as noopept, this compound can be described as focusing primarily on physical stimulation over that of cognitive stimulation.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
In one clinical trial[12], fasoracetam appeared to be well-tolerated at doses up to 800mg/day, however, the subjects were identified as possibly having glutamate hypofunction as a result of mutations in genes encoding variants of the metabotropic glutamate receptor.
One case report exists of an overdose consisting of a large dose of phenibut (10g) in combination with an unknown quantity of fasoracetam. Patient was found unconscious on the sidewalk and bradycardia (slowed heartbeat) was noted at the hospital, requiring the use of subcutaneous pacing pads. The patient recovered from the physical symptoms and was referred to a psychiatric unit for evaluation and treatment of an underlying condition. The case report notes that bradycardia is not typically reported in phenibut overdose and could possibly be related to fasoracetam.[13]
Lethal dosage
The median lethal dosage (LD50) of fasoracetam was reported as 300mg/kg in mice and 980mg/kg in rats.[14]
Tolerance and addiction potential
This substance has little history of human use. While tolerance and addiction or physical dependence have not been reported, the data on long-term use is lacking.
